- Home
- PHGE vs CNFR Comparison
PHGE vs CNFR Comparison
Compare PHGE & CNFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- CNFR
- Stock Information
- Founded
- PHGE 2015
- CNFR 2009
- Country
- PHGE Israel
- CNFR United States
- Employees
- PHGE N/A
- CNFR N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- CNFR Property-Casualty Insurers
- Sector
- PHGE Health Care
- CNFR Finance
- Exchange
- PHGE Nasdaq
- CNFR Nasdaq
- Market Cap
- PHGE 11.0M
- CNFR 9.4M
- IPO Year
- PHGE N/A
- CNFR 2015
- Fundamental
- Price
- PHGE $0.44
- CNFR $0.76
- Analyst Decision
- PHGE Strong Buy
- CNFR
- Analyst Count
- PHGE 1
- CNFR 0
- Target Price
- PHGE $15.00
- CNFR N/A
- AVG Volume (30 Days)
- PHGE 284.6K
- CNFR 2.7K
- Earning Date
- PHGE 08-13-2025
- CNFR 08-12-2025
- Dividend Yield
- PHGE N/A
- CNFR N/A
- EPS Growth
- PHGE N/A
- CNFR N/A
- EPS
- PHGE N/A
- CNFR 1.96
- Revenue
- PHGE N/A
- CNFR $64,021,000.00
- Revenue This Year
- PHGE N/A
- CNFR $25.91
- Revenue Next Year
- PHGE N/A
- CNFR N/A
- P/E Ratio
- PHGE N/A
- CNFR $0.39
- Revenue Growth
- PHGE N/A
- CNFR N/A
- 52 Week Low
- PHGE $0.34
- CNFR $0.42
- 52 Week High
- PHGE $3.86
- CNFR $1.91
- Technical
- Relative Strength Index (RSI)
- PHGE 43.34
- CNFR 48.37
- Support Level
- PHGE $0.43
- CNFR $0.73
- Resistance Level
- PHGE $0.48
- CNFR $0.81
- Average True Range (ATR)
- PHGE 0.05
- CNFR 0.02
- MACD
- PHGE 0.00
- CNFR -0.00
- Stochastic Oscillator
- PHGE 58.82
- CNFR 41.18
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.